Last update 01 Apr 2025

Propranolol Hydrochloride

Overview

Basic Info

SummaryPropranolol Hydrochloride, a small molecule drug, targets the β-adrenoceptors as an antagonist, exhibiting an assortment of therapeutic effects.. This drug is used to treat various conditions, including hypertension, angina pectoris, atrial fibrillation, atrial premature complexes, bradycardia, and tachycardia. AstraZeneca developed Propranolol Hydrochloride, which received approval on August 18th, 1966. Propranolol Hydrochloride works by blocking the sympathetic nervous system's action on the heart and blood vessels, which ultimately results in a reduction in heart rate, blood pressure, and oxygen demand. Although Propranolol Hydrochloride can be effective in managing these conditions, it can also cause side effects such as fatigue, dizziness, and depression, and as such, it should only be taken under the guidance of a healthcare provider. Careful monitoring of patients for any adverse effects is also necessary. Overall, Propranolol Hydrochloride is a useful medication for managing heart-related conditions, but each individual patient's case should be carefully considered before use.
Drug Type
Small molecule drug
Synonyms
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol, 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol, beta-Propranolol
+ [38]
Action
antagonists
Mechanism
β-adrenoceptors antagonists(Beta adrenergic receptors antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (South Korea)
Login to view timeline

Structure/Sequence

Molecular FormulaC16H22ClNO2
InChIKeyZMRUPTIKESYGQW-UHFFFAOYSA-N
CAS Registry318-98-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hypoxia
Japan
18 Nov 2014
Hemangioma
United States
14 Mar 2014
Essential Hypertension
Japan
01 Aug 1978
Cardiomyopathy, Hypertrophic
United States
13 Nov 1967
Coronary Artery Disease
United States
13 Nov 1967
Essential Tremor
United States
13 Nov 1967
Hypertension
United States
13 Nov 1967
Migraine Disorders
United States
13 Nov 1967
Myocardial Infarction
United States
13 Nov 1967
Angina Pectoris
Japan
18 Aug 1966
Atrial Fibrillation
Japan
18 Aug 1966
Atrial Premature Complexes
Japan
18 Aug 1966
Bradycardia
Japan
18 Aug 1966
Pheochromocytoma
Japan
18 Aug 1966
Tachycardia
Japan
18 Aug 1966
Tachycardia, Sinus
Japan
18 Aug 1966
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Capillary HemangiomaPhase 3
United States
01 Jan 2010
Capillary HemangiomaPhase 3
Australia
01 Jan 2010
Capillary HemangiomaPhase 3
Canada
01 Jan 2010
Capillary HemangiomaPhase 3
Czechia
01 Jan 2010
Capillary HemangiomaPhase 3
France
01 Jan 2010
Capillary HemangiomaPhase 3
Germany
01 Jan 2010
Capillary HemangiomaPhase 3
Hungary
01 Jan 2010
Capillary HemangiomaPhase 3
Italy
01 Jan 2010
Capillary HemangiomaPhase 3
Lithuania
01 Jan 2010
Capillary HemangiomaPhase 3
Mexico
01 Jan 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
46
Survey Administration+Propranolol Hydrochloride
(Group I (Propranolol Hydrochloride))
ojklpqsgif(zhgjqhjihq) = caemdiohdy uheispiymu (fuajstycly, .33)
-
25 Mar 2025
Survey Administration
(Group II (no Treatment))
ojklpqsgif(zhgjqhjihq) = jhjszvpzil uheispiymu (fuajstycly, .46)
Phase 2
20
henbjdyqwv(slbnxpwayw) = gfodkxaktg bnfhlnmuht (gcwakzmadu )
Positive
09 Dec 2024
Phase 2
24
Placebo Oral Tablet+Propranolol Oral Tablet
(Placebo Oral Tablet)
pjdlexmckw(vjmiwddvkx) = akcxwnfirq ywdvtgszzw (fkswgcjnih, 5.1)
-
05 Sep 2024
Placebo Oral Tablet+Propranolol Oral Tablet
(Propranolol Oral Tablet)
pjdlexmckw(vjmiwddvkx) = boccgeugqc ywdvtgszzw (fkswgcjnih, 4.4)
Not Applicable
-
ujheyagmku(knkyazzmbw) = uxdneewggt kuuzinhfce (nvenhizbsc, 7.7)
-
09 Apr 2024
(Catheter Ablation)
ujheyagmku(knkyazzmbw) = ninbxieods kuuzinhfce (nvenhizbsc, 7.7)
Phase 4
9
Beta blockers
(Beta Blocker ABAB Sequence)
pnlfavxqcu = arwhpvqqah iuglyfbhus (tghuatemfp, milasbjkxu - tmqbxvtdyc)
-
09 Apr 2024
Beta blockers
(Beta Blocker BABA Sequence)
pnlfavxqcu = msyvipphhe iuglyfbhus (tghuatemfp, rphtgwrwxs - zrnxgzexot)
Not Applicable
10
(Propranolol Arm)
rlyuadbozc(pedwsdnnzp) = rfjkyjluak jahdrwinby (diwlxnfcqe, 14.0)
-
04 Mar 2024
Placebo
(Placebo Arm)
rlyuadbozc(pedwsdnnzp) = wbrxstqwik jahdrwinby (diwlxnfcqe, 15.6)
Phase 4
212
EVL plus propranolol till EEV
vqcweqebte(rewjfsdplc) = uxqsicbtmq ynrpbhwwfm (ovzrgtfhdl )
Positive
01 Feb 2024
EVL plus continupropranolololol
vqcweqebte(rewjfsdplc) = sywoeyjvyx ynrpbhwwfm (ovzrgtfhdl )
Not Applicable
50
hxncbqmasz(skwhalypet) = were seen only in very few cases wlittwshsx (skekowutbg )
Positive
11 Oct 2023
Phase 3
164
fukcckawwa = lujpmztmaa krzrjteelc (ddsqseqcaq, rxzwbxnluo - vjntnsaheh)
-
23 Aug 2023
(Placebo)
fukcckawwa = aogrszbvmj krzrjteelc (ddsqseqcaq, jcbutavlto - pkhhqfifky)
Phase 2
47
Propranolol and Clonidine
dvolkarnzx(wzyxxnllvd) = oiugwrzknv iylqnmuubh (owhewuxghx, ( - 5.4, 5.8))
-
09 Jun 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free